[PRESS RELEASE] Newly Published Phase 3 Study in People with COVID-19 Shows SaNOtize Nitric Oxide Nasal Spray Reduced Viral Load by 99% within Two Days

VANCOUVER, British Columbia & MUMBAI, July 13, 2022–SaNOtize Research & Development Corp., (“SaNOtize”), a Canadian anti-infective-focused therapeutics company, and Glenmark Pharmaceuticals Limited (“Glenmark”), a global, innovation-driven pharmaceutical company, today published results of a Phase 3 clinical trial in The Lancet Regional Health Southeast Asia, illustrating the effectiveness of nitric oxide nasal spray (NONS™) for the treatment of adult patients with COVID-19.

Read more here.